中国P站

Atherosclerosis is a chronic inflammatory disease characterized by the progressive accumulation of lipid-rich plaques within the arterial walls, leading to vascular stenosis, impaired blood flow, and an increased risk of thrombotic events. While traditional risk factors such as dyslipidemia, hypertension, smoking, and diabetes have long been recognized as contributors to atherosclerosis, recent research has highlighted the role of homocysteine, a sulfur-containing amino acid, as a significant modulator of vascular dysfunction and plaque development. Elevated plasma homocysteine levels, known as hyperhomocysteinemia, have been associated with endothelial dysfunction, oxidative stress, inflammation, and prothrombotic states, all of which contribute to the pathogenesis and progression of atherosclerosis [1].

Homocysteine is a product of methionine metabolism, and its regulation depends on key enzymatic pathways, including remethylation and transsulfuration. Nutritional deficiencies in folate, vitamin B6, and vitamin B12 can impair homocysteine metabolism, leading to its accumulation in the bloodstream. Emerging evidence suggests that hyperhomocysteinemia may not only be a marker of cardiovascular disease but an active participant in the pathological processes driving vascular damage. Consequently, the exploration of homocysteine-lowering strategies, including dietary interventions and pharmacological approaches, has become an area of growing interest in cardiovascular research. This manuscript examines the molecular mechanisms through which homocysteine contributes to atherosclerosis, the clinical relevance of hyperhomocysteinemia, and potential therapeutic strategies aimed at mitigating its adverse vascular effects [2].

Description

The relationship between homocysteine and vascular health is multifaceted, involving endothelial dysfunction, oxidative stress, inflammation, and thrombosis. One of the primary mechanisms through which homocysteine promotes atherosclerosis is its deleterious effect on endothelial cells. The endothelium plays a crucial role in maintaining vascular homeostasis by regulating vasodilation, leukocyte adhesion, and coagulation balance. Elevated homocysteine levels induce endothelial cell dysfunction by reducing nitric oxide bioavailability, impairing endothelial-dependent vasodilation, and increasing the expression of adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1) and intracellular adhesion molecule-1 (ICAM-1). These changes promote leukocyte infiltration into the arterial intima, initiating the inflammatory cascade that drives atherosclerosis progression [3].

Oxidative stress is another critical pathway linking hyperhomocysteinemia to vascular damage. Homocysteine can undergo oxidation to form reactive oxygen species (ROS), which contribute to lipid peroxidation, protein oxidation, and DNA damage within vascular tissues. The overproduction of ROS not only exacerbates endothelial dysfunction but also enhances the oxidation of low-density lipoproteins (LDL), a key step in atherosclerotic plaque formation. Additionally, homocysteine promotes the activation of nuclear factor-kappa B (NF-κB), a transcription factor that upregulates pro-inflammatory cytokines, chemokines, and adhesion molecules, further amplifying the inflammatory response within the vasculature [4].

Hyperhomocysteinemia also plays a pivotal role in enhancing coagulation and thrombogenesis, increasing the risk of acute cardiovascular events such as myocardial infarction and stroke. Elevated homocysteine levels stimulate platelet aggregation and induce the expression of tissue factor, a key initiator of the coagulation cascade. Furthermore, homocysteine disrupts the balance between procoagulant and anticoagulant factors by reducing the activity of endothelial-derived anticoagulants such as thrombomodulin and protein C. The combined effects of endothelial dysfunction, oxidative stress, and hypercoagulability contribute to the accelerated progression of atherosclerosis and the heightened risk of thrombotic complications in individuals with elevated homocysteine levels [5].

From a clinical perspective, hyperhomocysteinemia is recognized as an independent risk factor for atherosclerotic cardiovascular disease, prompting efforts to identify potential therapeutic interventions. Dietary supplementation with folate, vitamin B6, and vitamin B12 has been shown to lower homocysteine levels by enhancing its metabolism through the remethylation and transsulfuration pathways [6]. Studies have demonstrated that folate supplementation effectively reduces plasma homocysteine concentrations, leading to improved endothelial function and reduced cardiovascular risk. However, large-scale randomized controlled trials evaluating the efficacy of homocysteine-lowering strategies in reducing cardiovascular events have yielded mixed results, indicating that homocysteine may act as a secondary contributor rather than a primary driver of atherosclerosis [7].

Beyond nutritional interventions, pharmacological approaches targeting homocysteine metabolism and oxidative stress are being explored. Antioxidant therapies, including N-acetylcysteine and polyphenols, have shown potential in mitigating homocysteine-induced oxidative damage and improving vascular health. Additionally, emerging research into enzyme-based therapies aims to enhance homocysteine catabolism through recombinant cystathionine beta-synthase (CBS) and betaine-homocysteine methyltransferase (BHMT) modulation. Gene-editing technologies such as CRISPR/Cas9 are also being investigated to correct genetic mutations associated with hyperhomocysteinemia, offering potential avenues for precision medicine in cardiovascular disease prevention [8].

Conclusion

The role of homocysteine in vascular atherosclerosis extends beyond being a mere biomarker of cardiovascular risk, actively contributing to endothelial dysfunction, oxidative stress, inflammation, and thrombosis. Hyperhomocysteinemia exacerbates atherosclerosis progression through multiple pathological pathways, making it an important target for therapeutic intervention. While dietary supplementation with folate and B vitamins effectively reduces plasma homocysteine levels, its impact on cardiovascular outcomes remains a subject of ongoing debate. Advances in antioxidant therapies, enzyme-based interventions, and gene-editing strategies hold promise for refining homocysteine-targeted approaches in atherosclerosis management.

Future research will need to focus on elucidating the precise mechanisms through which homocysteine interacts with other cardiovascular risk factors and determining the most effective strategies for mitigating its adverse effects. The integration of personalized medicine approaches, combining genetic risk assessments with targeted therapies, may enhance the precision of homocysteine-lowering interventions. As cardiovascular research continues to evolve, a deeper understanding of homocysteine’s role in vascular pathology will be essential in developing innovative strategies to reduce the burden of atherosclerosis and improve long-term cardiovascular health.

Acknowledgement

None

Conflict of Interest

None

References

1. Gimbrone MA Jr, Topper JN, Nagel T, Anderson KR, Garcia-Cardena G (2000) Ann N Y Acad Sci 902: 230-239.

   , ,

2. Campbell KA, Lipinski MJ, Doran AC, Skaflen MD, Fuster V, et al. (2012) Circ Res 110: 889-900.

   , ,

3. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, et al. (1999) Atherosclerosis 145: 33-43.

   , ,

4. Libby P, Ridker PM, Hansson GK (2011) Nature 473: 317-325.

   , ,

5. Camejo G, Lalaguna F, Lopez F, Starosta R (1980) Atherosclerosis 35: 307-320.

   , ,

6. Tabas I, Williams KJ, Boren J (2007) Circulation 116: 1832-1844.

   , ,

7. Frostegard J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H, (1990) . Proc Natl Acad Sci USA 87: 904-908.

   , ,

8. Frostegard J, Wu R, Giscombe R, Holm G, Lefvert AK, et al. (1992) Arterioscler Thromb 12: 461-467.

   , ,